Kalaris, AlloVir announce stockholder approval of merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2025
0mins
Should l Buy ?
Merger Approval: AlloVir stockholders voted in favor of all proposals at a special meeting, including the merger with Kalaris.
New Company Name and Trading: Post-merger, the combined entity will be named Kalaris Therapeutics and will trade on Nasdaq under the ticker KLRS.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
